Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

1(33.3%)

Phase 1

1(33.3%)

Phase 4

1(33.3%)

3Total

N/A(1)

Phase 1(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials

NCT00000772Phase 1Completed

A Phase I Open-Label Study of the Safety, Tolerance, and Pharmacokinetic Interactions of Combination Didanosine and Ribavirin in HIV-Positive Individuals

Role: collaborator

NCT00500578Phase 4Completed

Intermittent Use of Aerosolized Ribavirin for Treatment of RSV

Role: collaborator

NCT00002298Not ApplicableTerminated

The Safety and Effectiveness of Ribavirin in the Early Stages of HIV-Infection

Role: lead

All 3 trials loaded